{"organizations": [], "uuid": "143ae465cc03539d26afbcaea59c08ed9c827562", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-volitionrx-limited-announces-inter/brief-volitionrx-limited-announces-interim-results-from-680-subject-clinical-trial-in-colorectal-cancer-idUSASB0C7IE", "country": "US", "domain_rank": 408, "title": "BRIEF-Volitionrx Limited Announces Interim Results From 680-Subject Clinical Trial In Colorectal Cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.52, "site_type": "news", "published": "2018-02-27T05:22:00.000+02:00", "replies_count": 0, "uuid": "143ae465cc03539d26afbcaea59c08ed9c827562"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-volitionrx-limited-announces-inter/brief-volitionrx-limited-announces-interim-results-from-680-subject-clinical-trial-in-colorectal-cancer-idUSASB0C7IE", "ord_in_thread": 0, "title": "BRIEF-Volitionrx Limited Announces Interim Results From 680-Subject Clinical Trial In Colorectal Cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "volitionrx ltd", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Volitionrx Ltd:\n* VOLITIONRX LIMITED ANNOUNCES INTERIM RESULTS FROM 680-SUBJECT CLINICAL TRIAL IN COLORECTAL CANCER\n* VOLITIONRX - ‍STUDY DEMONSTRATES HIGH DETECTION RATES OF STAGE I CANCER,PRE-CANCEROUS ADENOMAS IN COLORECTAL CANCER SCREENING TRIAL FOR NU.Q BLOOD TEST​\n* VOLITIONRX LTD - ‍DATA IS EXPECTED FROM 680-SUBJECT CLINICAL TRIAL IN 2018​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-27T05:22:00.000+02:00", "crawled": "2018-02-27T14:44:00.004+02:00", "highlightTitle": ""}